| MeSH term | MeSH ID | Detail |
|---|---|---|
| Dental Pulp Calcification | D003784 | 2 associated lipids |
| Dental Pulp Exposure | D003789 | 1 associated lipids |
| Dental Pulp Necrosis | D003790 | 6 associated lipids |
| Dentin Dysplasia | D003805 | 1 associated lipids |
| Dermatomyositis | D003882 | 2 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Diabetic Angiopathies | D003925 | 20 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Saika M et al. | 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. | 2001 | Endocrinology | pmid:11356664 |
| Mackie PS et al. | Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. | 2001 | Br. J. Cancer | pmid:11286476 |
| Hofbauer LC et al. | Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. | 2001 | J. Rheumatol. | pmid:11327234 |
| Hofbauer LC and Heufelder AE | The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. | 2001 | Arthritis Rheum. | pmid:11229454 |
| Leach RJ et al. | The genetics of Paget's disease of the bone. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11231972 |
| Luger NM et al. | Osteoprotegerin diminishes advanced bone cancer pain. | 2001 | Cancer Res. | pmid:11358823 |
| Haynes DR et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. | 2001 | Rheumatology (Oxford) | pmid:11426018 |
| Szulc P et al. | Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11443182 |
| O'Brien EA et al. | Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. | 2001 | Bone | pmid:11182380 |
| Zhang YH et al. | Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. | 2001 | J. Biol. Chem. | pmid:11032840 |
| Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
| Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
| Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
| Thirunavukkarasu K et al. | Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. | 2001 | J. Biol. Chem. | pmid:11451955 |
| Yun TJ et al. | Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. | 2001 | J. Immunol. | pmid:11160187 |
| Stejskal D et al. | Osteoprotegerin, RANK, RANKL. | 2001 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:12426773 |
| Takemura M et al. | Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. | 2001 | Metab. Clin. Exp. | pmid:11172466 |
| Gravallese EM et al. | The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. | 2001 | Arthritis Res. | pmid:11178122 |
| Makiishi-Shimobayashi C et al. | Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11181055 |
| Brändström H et al. | Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162596 |
| Wuyts W et al. | Evaluation of the role of RANK and OPG genes in Paget's disease of bone. | 2001 | Bone | pmid:11165949 |
| Michigami T et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. | 2001 | Cancer Res. | pmid:11245477 |
| Wada N et al. | Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. | 2001 | J. Periodont. Res. | pmid:11246705 |
| Jung K et al. | Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. | 2001 | Clin. Chem. | pmid:11673385 |
| Lean JM et al. | FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. | 2001 | Blood | pmid:11675341 |
| Fiumara P et al. | Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. | 2001 | Blood | pmid:11675352 |
| Satoh K et al. | Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. | 2001 | Pancreas | pmid:11590320 |
| Yano K et al. | Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11594776 |
| Brown JM et al. | Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. | 2001 | Clin. Cancer Res. | pmid:11595685 |
| Price PA et al. | Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11597934 |
| Nemec K and Schubert-Zsilavecz M | [Future therapies for metabolic bone diseases. New concepts and targets]. | 2001 | Pharm Unserer Zeit | pmid:11715689 |
| Kuntz KA et al. | An immunohistochemical study of osteoprotegerin in the human dental pulp. | 2001 | J Endod | pmid:11716077 |
| Hofbauer LC and Schoppet M | Serum measurement of osteoprotegerin--clinical relevance and potential applications. | 2001 | Eur. J. Endocrinol. | pmid:11720890 |
| Ueland T et al. | Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. | 2001 | Eur. J. Endocrinol. | pmid:11720891 |
| Chikazu D et al. | Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. | 2001 | J. Bone Miner. Res. | pmid:11697804 |
| Khosla S | Minireview: the OPG/RANKL/RANK system. | 2001 | Endocrinology | pmid:11713196 |
| Seidel C et al. | Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. | 2001 | Blood | pmid:11568016 |
| Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
| Hocking LJ et al. | Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. | 2001 | Am. J. Hum. Genet. | pmid:11555792 |
| Hofbauer LC et al. | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. | 2001 | Cancer | pmid:11505389 |
| Hofbauer LC and Heufelder AE | Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. | 2001 | J. Mol. Med. | pmid:11485016 |
| Furuya D et al. | Immuno-PCR assay for homodimeric osteoprotegerin. | 2001 | Clin. Chem. | pmid:11468243 |
| Seck T et al. | Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. | 2001 | Eur. J. Endocrinol. | pmid:11454517 |
| Burguera B et al. | Leptin reduces ovariectomy-induced bone loss in rats. | 2001 | Endocrinology | pmid:11459801 |
| Yamagishi T et al. | Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. | 2001 | Endocrinology | pmid:11459812 |
| Ma YL et al. | Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. | 2001 | Endocrinology | pmid:11517184 |
| Bateman TA et al. | Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. | 2001 | J. Orthop. Res. | pmid:11518255 |
| Myoung H et al. | Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. | 2001 | J. Periodont. Res. | pmid:11519698 |
| Haynes DR et al. | The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. | 2001 | J Bone Joint Surg Br | pmid:11521937 |
| Hofbauer LC and Schoppet M | Osteoprotegerin: a link between osteoporosis and arterial calcification? | 2001 | Lancet | pmid:11498208 |
| Sakai A et al. | 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. | 2001 | J. Bone Miner. Metab. | pmid:11498729 |
| Ikeda T et al. | Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. | 2001 | J. Bone Miner. Res. | pmid:11499864 |
| Thomas GP et al. | Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. | 2001 | J. Endocrinol. | pmid:11479141 |
| Allan GF et al. | Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. | 2001 | Steroids | pmid:11546554 |
| Feige U | Osteoprotegerin. | 2001 | Ann. Rheum. Dis. | pmid:11890662 |
| Halladay DL et al. | Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. | 2001 | J. Cell. Biochem. | pmid:11746511 |
| Cao Y et al. | IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. | 2001 | Cell | pmid:11747812 |
| Chung H et al. | Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. | 2001 | J. Korean Med. Sci. | pmid:11748360 |
| Komuro H et al. | The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. | 2001 | Arthritis Rheum. | pmid:11762937 |
| Lindberg MK et al. | Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. | 2001 | J. Endocrinol. | pmid:11739008 |
| Giuliani N et al. | Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. | 2001 | Blood | pmid:11739153 |
| Croucher PI et al. | Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. | 2001 | Blood | pmid:11739154 |
| Dhore CR et al. | Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11742876 |
| Ramalho AC et al. | Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. | 2001 | Cytokine | pmid:11792122 |
| Yano K et al. | Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. | 2001 | J. Bone Miner. Metab. | pmid:11685652 |
| Kawahara N et al. | Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. | 2001 | Chem. Pharm. Bull. | pmid:11605678 |
| Sparks AB et al. | Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. | 2001 | Calcif. Tissue Int. | pmid:11351498 |
| Disthabanchong S and González EA | Regulation of bone cell development and function: implication for renal osteodystrophy. | 2001 | J. Investig. Med. | pmid:11352181 |
| Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |
| Yan T et al. | Regulation of osteoclastogenesis and RANK expression by TGF-beta1. | 2001 Aug 1-9 | J. Cell. Biochem. | pmid:11573248 |
| Rosa-Rañal M et al. | [New paradigms in the regulation of bone metabolism]. | 2001 Jul-Aug | Rev. Invest. Clin. | pmid:11599485 |
| Hofbauer LC et al. | Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. | 2002 | Eur. J. Endocrinol. | pmid:12153751 |
| Mundy GR | Metastasis to bone: causes, consequences and therapeutic opportunities. | 2002 | Nat. Rev. Cancer | pmid:12154351 |
| Lorget F et al. | Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12163011 |
| Ulrich-Vinther M et al. | Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. | 2002 | J Bone Joint Surg Am | pmid:12177271 |
| Ohmori H et al. | Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. | 2002 | J. Hum. Genet. | pmid:12181640 |
| Zou W and Bar-Shavit Z | Dual modulation of osteoclast differentiation by lipopolysaccharide. | 2002 | J. Bone Miner. Res. | pmid:12096834 |
| Koyama H et al. | Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. | 2002 | J. Bone Miner. Res. | pmid:12096835 |
| Langdahl BL et al. | Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. | 2002 | J. Bone Miner. Res. | pmid:12096838 |
| Zhang J et al. | Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. | 2002 | J. Bone Miner. Res. | pmid:12096839 |
| Treuheit MJ et al. | Inverse relationship of protein concentration and aggregation. | 2002 | Pharm. Res. | pmid:12033388 |
| Biskobing DM et al. | Novel therapeutic options for osteoporosis. | 2002 | Curr Opin Rheumatol | pmid:12118183 |
| Mizukami J et al. | Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. | 2002 | Mol. Cell. Biol. | pmid:11809792 |
| Wynne F et al. | Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. | 2002 | Calcif. Tissue Int. | pmid:12073153 |
| Lubberts E et al. | Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. | 2002 | Arthritis Rheum. | pmid:12428250 |
| Crotti TN et al. | Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. | 2002 | Ann. Rheum. Dis. | pmid:12429533 |
| Hofbauer LC and Schoppet M | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12432053 |
| Jono S et al. | Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. | 2002 | Circulation | pmid:12208791 |
| Ito S et al. | Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. | 2002 | J. Biol. Chem. | pmid:11733492 |
| Stajszczyk M | [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. | 2002 | Pol. Arch. Med. Wewn. | pmid:12600190 |
| Fahrleitner A et al. | Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. | 2002 | Wien. Klin. Wochenschr. | pmid:12602117 |
| Holen I et al. | Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. | 2002 | Cancer Res. | pmid:11912131 |
| Mori H et al. | RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. | 2002 | Histochem. Cell Biol. | pmid:11914926 |
| Scatena M and Giachelli C | The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. | 2002 | Trends Cardiovasc. Med. | pmid:11852256 |
| Hofbauer LC and Kühne CA | Cytokine inhibition: a new therapeutic avenue for skeletal diseases. | 2002 | Drug Discov. Today | pmid:11854049 |
| Viereck V et al. | Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. | 2002 | Biochem. Biophys. Res. Commun. | pmid:11855844 |
| Romas E et al. | Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. | 2002 | Bone | pmid:11856640 |
| Takayanagi H | [Cross-talk between immune and skeletal systems]. | 2002 | Nippon Rinsho | pmid:12510352 |
| Shimizu-Ishiura M et al. | Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. | 2002 | J Electron Microsc (Tokyo) | pmid:12455916 |
| Whyte MP and Hughes AE | Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. | 2002 | J. Bone Miner. Res. | pmid:11771666 |